BioStock: A new cancer project in Sprint Bioscience’s portfolio

In connection with the rights issue this summer, the biotechnology company Sprint Bioscience promised further investments in expanding the development portfolio. Now, about a week after completing the issue, the company has announced NIMA, a cancer project that targets a tumour’s microenvironment to affect the cancer’s ability to grow while at the same time making it easier for the immune system to attack it directly.

Read the full article at

This is a press release from BioStock – Connecting Innovation & Capital.